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A B S T R A C T
Bone sarcomas are a collection of sporadic malignancies of mesenchymal origin. The most common subtypes
include osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Despite the use of aggressive treatment
protocols consisting of extensive surgical resection, chemotherapy, and radiotherapy, outcomes have not sig-
nificantly improved over the past few decades for osteosarcoma or Ewing sarcoma patients. In addition, chon-
drosarcoma and chordoma are resistant to both chemotherapy and radiation therapy. There is, therefore, an
urgent need to elucidate which novel new therapies may affect bone sarcomas. Emerging checkpoint inhibitors
have generated considerable attention for their clinical success in a variety of human cancers, which has led to
works assessing their potential in bone sarcoma management. Here, we review the recent advances of anti-PD-1/
PD-L1 and anti-CTLA-4 blockade as well as other promising new immune checkpoint targets for their use in bone
sarcoma therapy.
1. Introduction
Bone sarcomas are a group of sporadic malignancies originating
from mesenchymal tissues. In the year 2018 within the United States,
approximately 3450 patients are expected to be newly diagnosed with a
primary bone sarcoma, representing less than 0.2% of all new cancers
[1]. Total deaths are approximated at 1590 total cases per year at a rate
of 0.4 deaths per 100,000 people [1,2]. Despite their relative in-
frequency, bone sarcomas are uniquely challenging with high rates of
fatality and overall burden of disease. Primary bone sarcomas affect
children, adolescents, as well as older patients, with age-specific in-
cidence varying according to histological subtype [3–8] (Table 1). The
most common bone sarcomas include osteosarcoma, Ewing sarcoma,
chondrosarcoma, and chordoma [1]. Bone sarcomas have a predilection
for pediatric and adolescent populations, as they comprise 6% of all
childhood cancers. Overall, osteosarcoma (56%) is much more common
than Ewing sarcoma (34%), chondrosarcoma (6%), and chordoma (less
than 5%) [1]. In adults, chondrosarcoma is the most common, as it
accounts for more than 40% of primary bone sarcomas, followed by
osteosarcoma (28%), chordoma (10%), Ewing sarcoma (8%), and un-
differentiated pleomorphic sarcoma (4%) (Fig. 1) [1]. These tumors
frequently arise from the long bones, especially of the lower extremity,
as well as the pelvis, vertebra, or sacrum for cases of chordoma (Fig. 2).
Clinically, the axial lesions tend to be more aggressive compared to
appendicular sarcomas.
The standard treatment protocol for osteosarcoma and Ewing sar-
coma consists of extensive surgical resection, chemotherapy, and ra-
diation. However, despite these aggressive interventions, patient out-
comes have not significantly improved for decades. According to data
from the Surveillance, Epidemiology, and End Results (SEER) Program
from 2008 to 2014, the five-year overall survival rate for patients with
bone sarcoma is 66.9% [2]. Relapse rates also remain high at ap-
proximately 35% [9]. Moreover, patients with metastatic disease have
an even worse prognosis, with five-year overall survival rates of ap-
proximately 10–30% [9,10]. Chemotherapeutic-resistant patients also
have poor outcomes, even with detailed regimen modifications [4,10].
While osteosarcoma and Ewing sarcoma can sometimes respond to
chemotherapy, chondrosarcoma and chordoma have well-known che-
motherapeutic and radiotherapeutic resistance which has contributed
to poor patient outcomes. Given these barriers to current treatment
regimens, there is an urgent need to identify which novel therapeutics
may improve management of bone sarcomas.
In recent years, immune modulating therapies have received con-
siderable attention for their efficacy in cancer treatment. These
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therapies largely function by attenuating the immune inhibitory mo-
lecules tumor cells employ to protect themselves from immune cells
within the tumor microenvironment. In the normal physiological state,
this process is important for regulating peripheral immune tolerance
and attenuating a potentially overzealous immune response [11].
However, cancer cells hijack this response. The first generation and
best-known checkpoint inhibitors are antibodies targeting programmed
cell death receptor-1 (PD-1) and its associated ligand (PD-L1), as well as
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies. The
anti-tumor immune response has shown impressive clinical results in
various tumors, including melanoma, non-small-cell lung cancer, renal
cell carcinoma, bladder cancer, and head and neck cancers [12–18]. Of
note, the 2018 Nobel Prize for Physiology or Medicine was awarded to
Dr. James P. Allison and Dr. Tasuku Honjo, for their respective dis-
coveries of CTLA-4 or PD-1 negative immune regulation as a novel
chemotherapeutic therapy. Their achievements have accelerated in-
vestigations into the potential of these therapies in bone sarcomas. Here
we review the application of immune checkpoint therapies, including
anti-PD-1/PD-L1 and anti-CTLA-4, for the treatment of common bone
sarcomas.
2. PD-1/PD-L1
PD-1 is a cell-surface protein receptor expressed on activated CD8+
T lymphocytes, B cells, and natural killer (NK) cells. PD-L1 (B7-H1 or
CD274) and PD-L2 (B7-DC or CD273) are often expressed on tumor cells
and tumor-infiltrating lymphocytes (TILs) within the tumor micro-
environment. Mechanistically, PD-1 expression is induced during T cell
activation and through the PD-1/PD-L1 pathway controls the induction
and maintenance of immune tolerance within the tumor
Fig. 1. Histologic subtypes of common bone sarcomas in pediatric and adolescent populations (A), and adults (B) [1,2].
Fig. 2. Anatomical distribution of common bone sarcomas [2–8].
P. Thanindratarn et al. Journal of Bone Oncology 15 (2019) 100221
3
microenvironment [19,20]. Engagement of PD-1 and its ligands PD-L1
or PD-L2 inhibits T cell activation, proliferation, and cytotoxic secretion
within cancer as well, resulting in an attenuated antitumor immune
response (Fig. 3).
Various solid tumors including melanoma, renal cell carcinoma,
non-small cell lung cancer, ovarian cancer, colorectal cancer, thymic
cancer, and Hodgkin's lymphoma have shown increased PD-L1 ex-
pression with associated metastasis and poorer overall outcomes for
patients [21,22]. Experimentally, blockage of the PD-1/PD-L1 pathway
has produced favorable results in these cancers [12–18]. At present,
nivolumab and pembrolizumab are the two FDA approved anti-PD-1
agents for the treatment of advanced melanoma, non-small cell lung
cancer, renal cell carcinoma, and Hodgkin's lymphoma [21,22].
In addition to these cancers, higher expression of PD-1 on immune
cells and PD-L1 on tumor cells have been reported in various subtypes
of bone and soft tissue sarcomas and correlated with poorer prognosis
[23–26]. While surgery remains principally important in bone sarcoma
treatment, recent advances in cancer immunotherapy have generated
considerable interest within the field for their potential to advance
current treatment strategies.
2.1. PD-1/PD-L1 in osteosarcoma
Osteosarcoma is the most common bone cancer in childhood and
second most common for adults (Fig. 1). It often develops at the me-
taphysis of long bones within the extremities (Fig. 2). In general, adult-
onset osteosarcomas primarily occur secondary to predisposing condi-
tions such as Paget's disease of bone, bone irradiation, bone infarction,
or other benign bone lesions. For Asian patients, however, there is a
much higher incidence of primary osteosarcoma tumors [2]. The five-
year overall survival for osteosarcoma is 54% in non-metastatic patients
and drops to less than 20% in cases of metastasis [2].
Several studies have examined PD-L1 expression in osteosarcoma
cell lines and tumor tissues and is summarized in Table 2 [26–34].
While PD-L1 expression in osteosarcoma cell lines broadly ranges from
low to high, the drug-resistant variants trend towards higher expression
compared to their parental cell lines [28]. Such findings have led to
subsequent biochemical research, including a study utilizing the Clus-
tered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9
system to target the PD-L1 gene in osteosarcoma cell lines [29]. Of
clinical interest, PD-L1 has been shown to regulate osteosarcoma cell
growth and drug resistance to doxorubicin and paclitaxel [29].
At the human osteosarcoma tissue level, 23.7% of osteosarcomas
demonstrate high expression and 50% show intermediate expression
Fig. 3. Overview of immune checkpoints under investigation in bone sarcomas.
Sarcoma cells are initially attacked by macrophages of the innate immune system. Dendritic cells capture tumor-associated antigens at the tumor site and present
them to T cells within the lymph node. After activation, the T cells return and kill tumor cells. This anti-tumor immune response is regulated by the immune
checkpoint mechanism. The PD-1/PD-L1 axis inhibits T cell activation, while the inhibitory effect of CTLA-4 is caused by competition between CD28 and CTLA-4
binding to B7-1/2 (CD80/86). Similarly, B7-H3 competitively binds CD28 and inhibits T cell activation. On the natural killer (NK) cells, NKG2D/NKG2DL stimulates
cytotoxic activity leading to tumor cells apoptosis. Various antibodies which affect these inhibitory and co-stimulatory immune checkpoints may enhance the anti-
tumor immune response in bone sarcoma patients. [18,19,63,66].
Abbreviations: Antigen-presenting cell (APC), B7 homolog 3 (B7-H3), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), major histocompatibility complex (MHC),
natural killer cell (NK), natural killer group 2D (NKG2D), natural killer group 2D ligand (NKG2DL), natural killer group 2D chimeric antigen receptor (NKG2D CAR), program
cell death receptor-1 (PD-1), program cell death receptor-1/2 ligand (PD-L1/PD-L2), tumor-associated antigen (TAA), T cell receptor (TCR).
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[28]. This is clinically significant, as expression of PD-L1 correlates
with TILs, which often mark metastasis and poorer outcomes [28].
Other studies support these findings and are summarized in Table 2
[30–34]. In a recent systematic meta-analysis of 14 studies with 868
total patients, osteosarcoma had 14–75% higher PD-L1 expression in
tumor tissues and significantly correlated with metastasis, mortality
risk, and poorer overall survival [23]. The differences of obtained PD-
L1 expression among the eligible studies may have resulted from var-
iations in primary antibodies, staining protocols, evaluating methods of
expression, and cutoff values for positivity, which make direct cross-
study comparisons challenging. Other studies have also shown higher
PD-L1 expression in metastatic tumor tissues, especially within the
lung, compared to primary tumor tissues [32,35].
Preclinical osteosarcoma mouse model work has shown promising
results of anti-PD-1 and anti-PD-L1 blockade therapy [36,37]. Specifi-
cally, in an anti-PD-1-antibody-treated humanized mouse model of os-
teosarcoma, there was significantly fewer pulmonary metastasis com-
pared to control [36]. Similar results were seen in a study investigating
the effects of a triple antibody therapy consisting of anti-PD-1, anti-PD-
L1, and anti-OX40 (Tumor necrosis factor receptor superfamily,
member 4 (TNFRSF4), CD134) in mice transplanted with osteosarcoma.
The treatment group had significantly longer survival times compared
to the control group, with 50% of the treatment group having no lung
metastasis on computerized tomographic (CT) imaging or histological
follow-up [37]. These mouse model results show anti-PD-1 and anti-PD-
L1 blockade therapy to be potentially promising therapies for patients
with advanced osteosarcoma.
In a multicenter phase II trial of anti-PD-1 immunotherapy (pem-
brolizumab) in advanced bone and soft tissue sarcomas (SARC028), 2 of
40 (5%) bone sarcoma patients had an objective response, including in
1 of the 22 osteosarcoma patients [38]. The most frequent grade 3 or
worse immune-related adverse events (irAEs) were anemia (14%), de-
creased lymphocyte count (12%), prolonged activated partial throm-
boplastin time (10%), and decreased platelet count (7%) [38]. Five
patients in the bone sarcoma group had non-fatal treatment-related
serious adverse events such as pneumonitis, interstitial nephritis, and
bone pain [38]. Interestingly, PD-L1 expression was observed in only 3
of 70 samples in this trial, all of which were from undifferentiated
pleomorphic sarcoma patients in the soft tissue sarcoma group [38]. We
enumerate the ongoing early phase clinical trials using anti-PD-1 and
anti-PD-L1 antibodies for osteosarcomas in Table 3.
2.2. PD-1/PD-L1 in Ewing sarcoma
Ewing sarcoma is a malignant bone or soft tissue tumor that mainly
occurs in childhood with a peak incidence at 15 years of age [5]. The
bone lesions often arise in the diaphysis of the lower extremity, pelvis,
upper extremity, and vertebrae (Fig. 2). Although the 5-year survival
rate of localized Ewing sarcoma is 70–80% [5], patient outcomes are
considerably worse for those with pelvic involvement, large tumors, or
incomplete tumor regression after chemotherapy. In addition, those
having metastatic involvement upon initial diagnosis have a 5-year
survival of less than 30% [5]. Ewing sarcoma is well-known for its
translocation of the EWS gene on chromosome 22 with the FLI1 gene on
chromosome 11, as it occurs in more than 90% of cases. However, the
EWS gene has a number of less recognizable fusion partners as well,
including ETV1, ERG, or the EA1F gene [39]. This genomic instability
forms numerous aberrant protein products potentially recognizable by
the immune system and is the rationale for strengthening the host im-
mune response through checkpoint blockade.
In a recent study, PD-L1 expression was observed in 39% of Ewing
sarcoma tissues and correlated with treatment response and clinical
outcome [34]. In a cohort immunohistochemical analysis of 370 Ewing
sarcoma tissue samples, PD-L1 was expressed in 19.2% of the samples
while PD-1 expression was 25.7% [40]. Of note, metastatic tumors
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tumors [40]. While TILs were also found in 15.4% of the samples in the
same study, there was no significant correlation between TILs and
histological subtype, location, PD-1 expression, PD-L1 expression,
clinical outcome, or prognosis [40]. More supportive evidence was
found in another analysis of PD-L1 expression in patients with soft
tissue sarcomas, as 33% of Ewing sarcoma tissue samples expressed PD-
L1 and significantly correlated with shorter survival time [41]. We
outline these studies and more in Table 4.
Despite robust preclinical data, the clinical application of anti-PD-1
blockade in Ewing sarcoma remains largely unexplored. In a case re-
port, a heavily pre-treated patient with recurrent metastatic Ewing
sarcoma of the vertebral bodies experienced complete resolution of
pulmonary metastases and vertebral and paravertebral soft tissue le-
sions following nine cycles of pembrolizumab therapy without serious
irAEs [39]. A more recent phase II trial evaluated the efficacy of
pembrolizumab for advanced soft tissue and bone sarcomas (SARC028),
with 13 Ewing sarcoma patients enrolled in the bone sarcoma group
[38]. However, none of these patients had an objective response, in-
cluding 11 patients (85%) with progressive disease and 2 patients
(15%) with stable disease [38]. Because Ewing sarcoma has consider-
able genomic instability, this may contribute to the variable patient
response to anti-PD-1 blockade; nevertheless, this treatment should not
be utilized for patients with Ewing sarcoma outside of clinical trials
given the poor responses in the SARC028 trial. The variability of clin-
ical response underlines the need for revealing which predictive bio-
markers correlate with a strong response to anti-PD-1 therapy. The
ongoing clinical trials assessing anti-PD-1 blockade therapy for Ewing
sarcoma are summarized in Table 3.
2.3. PD-1/PD-L1 in chondrosarcoma
Chondrosarcomas are cartilaginous bone malignancies with in-
creasing incidence up to 75 years of age [6,7]. Conventional chon-
drosarcomas account for nearly 90% of all chondrosarcomas and are
mostly low to intermediate-grade malignancies [6,7]. The prominent
sites affected include the metaphysis of the long bones, pelvis, shoulder
girdle, ribs, and sternum, with axial lesions often presenting with a
higher-grade appearance [6,7]. Except for the mesenchymal subtype,
most chondrosarcomas are relatively resistant to chemotherapy and
radiation. Clinical outcomes range from a 24% 5-year survival rate for
dedifferentiated chondrosarcoma to an 90% 5-year survival for con-
ventional chondrosarcoma [6,7].
Several immunohistochemical studies have focused on PD-1 and PD-
L1 in chondrosarcoma and are listed in Table 5 [26,42,43]. Increased
expression of PD-1 was observed within chondrosarcoma tissues com-
pared to healthy bone tissue controls and benign osteochondromas
[26]. PD-L1 expression has also been studied in various subtypes of
chondrosarcomas with significant results. Expression of PD-L1 was
observed in 41% of dedifferentiated chondrosarcomas and significantly
correlated with TILs and HLA class I expression, but not for overall
survival [42]. A more recent study revealed PD-L1 expression in 67.8%
and PD-L2 expression in 42.4% of 59 conventional chondrosarcoma
tissue samples [43]. Investigators found PD-L1 expression to correlate
with younger age (<30 years), larger tumor size (>10 cm), high tumor
grade, and recurrence [43]. When evaluated in tandem, combined PD-
L1 and PD-L2 expression significantly correlated with earlier recurrence
as well [43]. Overall, these findings support the potential of anti-PD-1
blockade therapy for the treatment of chondrosarcoma within clinical
trials.
Despite promising preclinical work, clinical studies of immune
checkpoint inhibitors in chondrosarcoma remain sparse, as the majority
of available data has been drawn from clinical trials focused on diverse
sarcoma types. In the SARC028 clinical trial, one of five chon-
drosarcoma patients treated with pembrolizumab had an objective re-
sponse [38]. Another study showed a partial response in a 74-year-old
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nivolumab [44]. Ongoing early phase clinical trials on chon-
drosarcomas are testing immune checkpoint blockades in combination
with the anti-CTLA-4 inhibitor (NCT02982486) and mTOR inhibitor
(NCT03190174), as shown in Table 3.
2.4. PD-1/PD-L1 in chordoma
Chordomas are very rare bone malignancies with a high rate of
recurrence. Their incidence is 0.08 per 100,000 people and peaks
during the sixth decade of life [8]. The chordomas which occur in those
less than 40 years of age account for less than 5% of all chordoma cases.
The most common sites for chordomas include the sacrum, skull base,
and vertebra (Fig. 2). Despite their overall infrequency, chordomas
constitute over 50% of all primary neoplasms in the sacrum. Their in-
sidious onset and local invasion of vital nervous system structures
complicates clinical management and is a significant contributor to
morbidity and mortality. The survival analysis of chordoma from the
SEER database reports 67.6%, 39.9%, and 13.1% 5-year, 10-year, and
20-year overall survival rates respectively, with a median survival of
6.29 years [2,8].
Previous investigation has shown PD-L1 to have considerable var-
iation of expression in chordoma cell lines [45]. Interestingly, in this
same work, 94.9% of 78 chordoma tissue samples stained positive for
PD-L1 [45]. The expression of PD-L1 significantly correlated with ele-
vated TILs and metastasis [45]. In another study focused on spinal
chordomas, 68.5% of 54 chordoma tissue samples were positive for
both PD-1 and PD-L1 expression, 70.4% of which had positive PD-1
expression in TILs [46]. PD-L1 expression was significantly associated
with advanced stage and TILs. Moreover, multivariate analysis revealed
PD-L1 expression in TILs as an independent predictor for poor local
recurrence-free survival and overall survival [46]. In another work,
TILs were observed in six out of ten chordoma tissue samples, three of
which had PD-1 expression and four of which had PD-L1 expression in
areas of tissue associated macrophages and TILs [47]. These studies,
which help elucidate immune checkpoint therapy for chordomas, are
summarized in Table 6.
Several ongoing clinical trials are evaluating the utility of anti-PD-1
and anti-PD-L1 agents in chordoma patients, as summarized in Table 3.
Of these, one trial is employing the use of nivolumab (NCT03173950).
Another phase I trial is investigating the safety and efficacy of nivo-
lumab combined with stereotactic radiosurgery in patients with re-
current, advanced, or metastatic chordoma (NCT02989636). Recruit-
ment is also underway for the DART trial (Dual Anti-CTLA-4 and Anti-
PD-1 blockade in Rare Tumors, NCT02834013) which seeks to evaluate
the clinical response and toxicities of ipilimumab plus nivolumab
combination therapy in chordoma. The results of these trials have ex-
pected publication dates in the near future.
3. CTLA-4
CTLA-4 (CD152) is a protein receptor expressed on the T lympho-
cyte surface that plays a crucial role during T cell activation. In normal
immunity, T cell activation is initiated when antigen is presented to the
T cell receptor (TCR) by MHC class I or II on the antigen presenting cell
(APC), which is amplified by a costimulatory signal in the form of CD28
on the T cell binding to B7-1 (CD80) or B7-2 (CD86) on tumor cells or
APCs [48]. Following this activation, CTLA-4 is potentially transported
from an intracellular compartment to the T cell surface, where it binds
to B7-1 and B7-2 with greater affinity than CD28 and subsequently
downregulates the immune response, as shown in Fig. 3 [48]. This is a
mechanism of peripheral tolerance to mitigate an overactivated im-
mune response in a normal physiological state. CTLA-4 inhibitory sig-
nals are quite complex, as they may also inhibit interleukin-2 tran-
scription within the T cells, Src homology domain-containing tyrosine
phosphatases (SHP-1, SHP-2, and PP2A), and trans-endocytosis of B7-1
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(Treg) which control effector T lymphocyte function and promote im-
mune tolerance [48]. As expected, blockade of the CTLA-4 receptor
increases CD8+ T lymphocyte activation and depletes Treg action.
Allison and co-workers demonstrated that combining anti-CTLA-4 an-
tibody with tumor lysate-loaded dendritic cells increased CD8+ TIL,
reduced Tregs, inhibited metastasis, and prolonged survival in a mouse
model with colon cancer or fibrosarcoma [49]. In another notable
work, a human monoclonal IgG1 anti-CTLA-4 antibody (also known as
ipilimumab) markedly lengthened median overall survival for meta-
static melanoma patients [50,51]. Thus far, anti-CTLA-4 blockade has
been successfully used to treat advanced melanoma and carcinomas
such as non-small cell lung cancer, renal cell carcinoma, and prostate
cancer [52–54]. As a prominent breakthrough treatment, researchers
are exploring its potential for other solid tumors, including bone sar-
comas.
In a phase I clinical trial of advanced stage pediatric solid tumors, 6
of 33 patients had progression stabilization with ipilimumab, including
2 (25%) of 8 osteosarcoma patients with acceptable irAEs [55]. Inter-
estingly, the overall survival was better in patients with irAEs compared
to those without irAEs [55]. Emerging clinical data suggests anti-CTLA-
4 antibody therapy may be most useful as part of a combination therapy
rather than a stand-alone monotherapy [56].
4. Combination immunotherapy in bone sarcomas
4.1. Combination PD-1 and CTLA-4 blockade therapy
The ultimate goal of checkpoint blockade immunotherapy is to
achieve long-term disease control in patients unresponsive to current
treatment options. To this end, checkpoint blockade combination
therapy is an emerging strategy for improving efficacy with acceptable
toxicity. In a double-blind study of combined ipilimumab and nivo-
lumab treatment in 142 patients with untreated advanced melanoma,
there was an overall response rate of 61% versus 11% in the ipili-
mumab-monotherapy group, with 22% compared to 0 % having a
complete response [56]. These results granted combination ipili-
mumab/nivolumab therapy FDA approval for advanced melanoma and
have since prompted a combination-based approach for various other
cancers, including bone sarcoma. In an osteosarcoma mouse model
study, a combination therapy of anti-PD-L1 with anti-CTLA-4 antibody
completely controlled metastatic osteosarcoma and showed a long-term
disease-free survival of 60%. This was markedly better than the 0%
long-term disease-free survival seen in the mice receiving anti-PD-L1
blockade monotherapy [57]. In a phase II study of nivolumab with or
without ipilimumab for metastatic sarcoma (Alliance A091401), the
number of confirmed responses was 2 (5%) of 38 patients in the nivo-
lumab group and 6 (16%) of 38 patients in the combined group [58].
Median progression-free survival and overall survival in the combina-
tion group were 4.1 and 14.3 months, respectively, which was much
improved over the 1.7 and 10.7 months seen in the monotherapy group.
There were, however, no objective responses seen in the nine patients
with bone sarcomas in either group [58]. Serious irAEs occurred in 8
(19%) of 42 patients receiving monotherapy and 11 (26%) of the 42
patients receiving combination therapy; there were no treatment-re-
lated deaths in either group [58]. In summary, while this clinical trial is
ongoing (NCT02500797), combination therapy has already demon-
strated improved efficacy and a manageable safety profile compared to
current treatment options in preclinical models. In Table 3, we analyze
various early phase clinical trials focused on osteosarcoma treatment
regimens composed of combination anti-PD-1/PD-L1 and anti-CTLA-4
blockade therapy alone or with other chemotherapeutics.
4.2. Combination immune checkpoint blockade and radiation
Although radiation therapy has classically been considered a mea-
sure of pure local control, amounting evidence has shown radiation
alone can improve systemic immune response and regress distant me-
tastasis, a phenomenon known as “the abscopal effect” [59]. This an-
titumor immune response is largely explained by a strengthened CD4+
and CD8+ T lymphocyte response [60] and a likely contributing factor
of enhanced immune checkpoint blockade response. The addition of
immune checkpoint inhibition with radiotherapy therefore has the
potential to improve clinical outcomes, and is evidenced in patients
with bone sarcomas with concurrent micro-metastasis [61].
Previous case series have suggested the synergistic effect of ipili-
mumab with multiple fraction radiation on out-of-field lesions of me-
tastatic melanoma [62]. Ongoing clinical trials are investigating the
combination of immune checkpoint blockade, especially PD-1, PD-L1,
and CTLA-4, with radiation in patients with advanced melanoma, non-
small cell lung cancer, head and neck cancer, liver cancer, prostate
cancer, and lymphoma [63]. To our acknowledge, there are no rando-
mized controlled trials showing immune checkpoint blockade therapy
combined with radiation to be superior to single treatment alone in
treatment-naïve patients. Moreover, the clinical trials recruiting bone
sarcoma patients for this treatment regimen is scarce. There is, how-
ever, an ongoing phase I trial comparing combination nivolumab with
stereotactic radiosurgery to nivolumab alone in the treatment of ad-
vanced chordoma (NCT02989636). As this trial is still active, no results
have yet been published.
4.3. Combination immune checkpoint blockade and targeted therapy or
chemotherapy
Although studies of combination immune checkpoint blockade
therapy, chemotherapy, or targeted therapy have expanded for soft
tissue sarcomas, including with cyclophosphamide (NCT02406781),
trabectedin (NCT03138161), doxorubicin (NCT02888665), gemcita-
bine (NCT03123276), or dasatinib (NCT01643278), recruitment for
study in their bone sarcoma counterparts have been relatively limited.
A previous retrospective trial studied the effect of nivolumab with pa-
zopanib, a tyrosine kinase vascular endothelial growth factor inhibitor,
in a group of 28 sarcoma patients which included four bone sarcoma
patients [44]. There were three partial responses observed, which in-
cluded a case of dedifferentiated chondrosarcoma, epithelioid sarcoma,
and maxillary osteosarcoma, with the last two patients having received
concomitant pazopanib [44]. Of note, a clinical benefit was observed in
half of the evaluable patients after >4 cycles of nivolumab. The on-
going trials investigating a combination of targeted therapy or che-
motherapy with immune checkpoint blockade are shown in Table 3.
5. Other immune checkpoints studied in bone sarcoma
5.1. B7-H3
B7 homolog 3 (B7-H3, CD276) is an inhibitory protein of the B7-
CD28 family with vital roles in the inhibition of T cell activation,
proliferation, and cytokine production (Fig. 3) [64]. It is expressed in
various other immune cells as well, including APCs, NK cells, and B
cells. B7-H3 overexpression is present in multiple cancers such as
melanoma, non-small-cell lung cancer, osteosarcoma, and rhabdo-
myosarcoma [64–66]. Notably, it is expressed in 91.8% of osteo-
sarcoma tissues, which is significantly higher than adjacent healthy
tissue, osteochondroma, and fibrous dysplasia [65]. Tumor B7-H3 ex-
pression inversely correlates with the number of TILs and promotes
osteosarcoma cell invasion [65]. It has also been reported that patients
with high B7-H3 expression levels have significantly shorter survival
and recurrence times compared to those with low expression [65].
As a result of these findings, there has been an expansion of work
focused on the efficacy of antibodies against B7-H3. Enoblituzumab
(MGA271), a humanized IgG1 monoclonal antagonistic B7-H3 anti-
body, has been studied in a phase I clinical trial in patients with re-
fractory B7-H3-expressing neoplasms such as melanoma and advanced
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solid tumors (NCT01391143). Patients experienced stable disease (>12
weeks) and 2–69% tumor shrinkage with good tolerance and no dose-
limiting toxicity. Another ongoing study is investigating enoblituzumab
in children with B7-H3-expressing solid tumors such as neuroblastoma,
rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms’ tumor, and
desmoplastic small round cell tumors (NCT02982941). MGD-009, a
humanized dual affinity re-targeting (DART) protein that binds both
CD3 on T cells and B7-H3 on its target cell, is another agent in an on-
going phase I clinical trial for patients with mesothelioma, melanoma,
non-small cell lung cancer, head and neck squamous cell carcinoma, or
soft tissue sarcoma (NCT02628535).
5.2. NKG2D/NKG2DL
NK cell activating receptor group 2 member D (NKG2D) and its
associated ligand (NKG2DL) have crucial roles in innate immunity.
Functionally, NKG2D is a co-stimulatory transmembrane protein re-
ceptor belonging to the CD94/NKG2 family and is found in CD8+ T
lymphocytes, some γδ T cells, and activated macrophages [67].
NKG2DLs are rarely expressed in healthy cells, as they are primarily
upregulated in response to infection and malignant transformation
[67]. At the cellular level, binding of NKG2D/NKG2DLs triggers NK cell
activation via PI3K (phosphatidylinositol-3 kinase) and Grb2-Vav1
(growth factor receptor-bound protein 2, vav guanine nucleotide ex-
change factor 1) pathways, resulting in the release of cytotoxic granules
and eventual tumor cell apoptosis [67]. As a protective mechanism,
advanced cancer cells can evade this immunosurveillance by down-
regulating or shedding NKG2DLs [67]. In summary, NKG2DL expres-
sion, its downstream pathway, and NK cell cytotoxicity are all instru-
mental in the NKG2D/NKG2DL system and promising areas for novel
cancer research.
To this point, one such study revealed moderate to high levels of
NKG2DL expression in all 22 osteosarcoma cell lines they investigated
[68]. Of these cell lines, every one of the 14 primary osteosarcoma cell
lines under investigation was sensitive to the cytotoxicity induced from
an NK cell-mediated NKG2D/NKG2DL interaction. However, higher
expression of NKG2DLs did not correlate with increased sensitivity
[68]. The authors also found that spironolactone, a diuretic drug, could
upregulate NKG2DL expression in primary osteosarcoma cell lines and
significantly increased the sensitivity of tumor cells to NK cell mediated
cytotoxicity from a NKG2D/NKG2DL interaction [68]. Another work
showed significantly increased cytolytic activity of NKG2D-CAR+
(chimeric antigen receptor) T-lymphocytes against osteosarcoma cell
lines in vitro and in murine osteosarcoma while preserving healthy cells
[69] A recent study was conducted on the effectiveness of γδ T cell
based immunotherapy combined with the DNA demethylating drug
decitabine in osteosarcoma [70]. They showed good results, as decita-
bine increased osteosarcoma cell NKG2D ligand expression which
subsequently increased their vulnerability to cytotoxic γδ T cells [70].
They investigated Ewing sarcoma in this same study and with flow
cytometry showed 14 different Ewing sarcoma cell lines broadly ex-
press NKG2DL [71]. The authors also used a lentivirus to fuse a CD3ζ/
CD28-derived signaling domain to NKG2D to create NKG2D-CAR+ T
lymphocytes capable of evoking Ewing sarcoma cell death [71]. These
results have prompted researchers to explore additional ways of
strengthening the NKG2D/NKG2DL axis in bone sarcomas.
5.3. HLA-G
Recently, the non-classical MHC class I molecule HLA-G has been
recognized for its important role in regulating immune responses. HLA-
G has an inhibitory effect on the NK cell and T cell response and is
expressed on mesenchymal stromal cells, T lymphocytes, and various
cancers. One recent study showed HLA-G expression in 34.0% of pre-
treated Ewing sarcoma biopsies and 33.3% of relapsed tumor biopsies
with regards to both the tumor cells and TILs [72]. While HLA-G
expression significantly correlates with increased TILs, no association
has been made with other clinical variables [72]. The authors posit that
modulation of HLA-G expression within the tumor microenvironment
might attenuate resistance to NK cell therapy and therefore enhance the
efficacy of immunotherapy for Ewing sarcoma. However, further work
is needed to better verify this proposed effect.
6. Future direction
Immune checkpoint inhibitors are generating considerable interest
for their potential in bone sarcoma treatment, and will likely continue
to do so as ongoing clinical trials begin to report on their results. At
present, studies have shown highly variable levels of PD-1 and PD-L1
expression in bone sarcomas as well as their inverse correlation with
prognosis. However, as of now, PD-1 and PD-L1 expression has not
reliably predicted patient response to treatment [73]. As this is an
emerging field in sarcoma research, future study is needed to better
analyze this phenomenon. As there is a high variability of PD-1 and PD-
L1 expression in patients, it may be useful to identity biomarkers for the
initiation of blockade therapy. In addition, as the prognostic and pre-
dictive value of TILs, MHC, PD-1/PD-L1, and CTLA-4 continues to
emerge within the cancer immunotherapy literatures, it is likely that
standardized screening biomarkers will be revealed. From this, the best
candidates for immune checkpoint therapy may become evident espe-
cially as emerging technologies such as liquid biopsy make personalized
medicine less invasive in sarcoma therapy [74].
Combination immune checkpoint blockade treatment regimens
have demonstrated a superior clinical response compared to single
checkpoint blockade therapy. It is therefore essential to find and titrate
the appropriate combination of checkpoint blockade drugs which has
acceptable irAEs while maintaining maximum efficacy. This is an active
area of investigation, especially within the realm of chemotherapy for
immunocompromised patients.
We have reviewed the major and emerging checkpoint inhibitors for
bone sarcomas herein. There are, however, a number of newer immune
checkpoint targets such as LAG-3, TIM3, VISTA, OX40, GITR, 4-1BB,
and IDO which have shown promising results in various cancers such as
melanoma, breast cancer, non-small cell lung cancer, renal cell carci-
noma, and squamous cell carcinoma of head and neck [75]. Few data
exist for these newer targets in bone sarcoma, and the efficacy of their
inhibition within bone and soft tissue sarcomas is relatively unknown.
7. Conclusion
Immune checkpoint blockade therapy has demonstrated remarkable
clinical outcomes in malignancies such as metastatic melanoma, renal
cell carcinoma, lung cancer, and breast cancer. As an emerging ther-
apeutic approach, these achievements have driven research seeking to
reveal their potential for patients with bone sarcomas. Much of the
current sarcoma research, from the basic studies to the clinical trials of
immune checkpoint blockade, are under ongoing investigation with
results expected to be published in the near future. Primary outcomes
for these trials include efficacy of treatment in various bone sarcomas as
a single agent or as combination therapy and their potential immune-
related adverse effects. Continued clinical trial efforts are especially
crucial for bone sarcomas, as they are a heterogeneous group of tumors
which require detailed study to accurately capture all immune check-
point targets. Discovery of predictive biomarkers for the efficacy is also
an essential next step, as this may allow for personalized medicine
within the field of bone sarcomas related immune checkpoint blockade
therapy.
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